Want to see GEHC full AI Analyst Report?
EBIT by Segment
Analyzes earnings before interest and taxes across different business segments, providing insight into which areas are most profitable and where there may be challenges or opportunities.Pharma Diagnostics is the steady earnings engine, while the recast AIS (Imaging + Advanced Visualization) shows meaningful margin uplift and is driving recent profitability momentum. Patient Care Solutions has swung to a material drag—now negative—and is the most acute near‑term risk, prompting a strategic review/possible disposition. Management’s record backlog and book‑to‑bill support the promised H2 margin step‑up, but inflation, component costs and China headwinds leave execution risk before NPIs and Flyrcado fully offset PCS weakness.
Date | Other | Imaging | Advanced Visualization Solutions | Patient Care Solutions | Pharmaceutical Diagnostics | Advanced Imaging Solutions |
|---|---|---|---|---|---|---|
Sep 30, 2026 | -$1.00M | $0.00 | $0.00 | $68.00M | $253.00M | $593.00M |
Jun 30, 2026 | $1.00M | $0.00 | $0.00 | -$26.00M | $250.00M | $525.00M |
Mar 31, 2026 | $5.00M | $180.00M | $299.00M | $10.00M | $197.00M | $0.00 |
Dec 31, 2025 | $2.00M | $264.00M | $376.00M | $74.00M | $234.00M | $0.00 |
Sep 30, 2025 | $2.00M | $240.00M | $271.00M | $27.00M | $220.00M | $0.00 |
Jun 30, 2025 | $1.00M | $188.00M | $267.00M | $60.00M | $213.00M | $0.00 |
Mar 31, 2025 | $2.00M | $199.00M | $261.00M | $48.00M | $205.00M | $0.00 |
Dec 31, 2024 | $1.00M | $149.00M | $526.00M | $106.00M | $212.00M | $0.00 |
Sep 30, 2024 | $1.00M | $287.00M | $232.00M | $82.00M | $193.00M | $0.00 |
Jun 30, 2024 | $1.00M | $286.00M | $178.00M | $78.00M | $200.00M | $0.00 |